Self-Monitoring and Management of Blood Pressure in Patients with Stroke or TIA:An Economic Evaluation of TEST-BP, A Randomised Controlled Trial

Kim, Lois G, Wilson, Edward C F, Davison, William J, Clark, Allan B, Myint, Phyo K and Potter, John F (2020) Self-Monitoring and Management of Blood Pressure in Patients with Stroke or TIA:An Economic Evaluation of TEST-BP, A Randomised Controlled Trial. PharmacoEconomics - Open. ISSN 2509-4262

[img]
Preview
PDF (Published_Version) - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (962kB) | Preview
[img] PDF (Accepted_Manuscript) - Submitted Version
Restricted to Repository staff only until 31 December 2099.

Download (1MB) | Request a copy

Abstract

Background: Prevention of secondary stroke following initial ictus is an important focus of after-stroke care. Blood pressure (BP) is a key risk factor so usual care following stroke or transient ischaemic attack includes regular BP checks and monitoring of anti-hypertensive medication. This is traditionally carried out in primary care, but the evidence supporting self-monitoring and self-guided management of BP in the general population with hypertension is growing. Objective: To estimate the cost-effectiveness of treatment as usual (TAU) vs (1) self-monitoring of BP (S-MON), and (2) self-monitoring and guided self-management of antihypertensive medication (S-MAN). Methods: Within-trial economic evaluation of a randomised controlled trial estimating the incremental cost per 1mmHg reduction in BP and per QALY gained over a six month time horizon from the perspective of the UK NHS. Results: Data were evaluable on 140 participants. Costs per patient were £473, £853 and £1035; mean reduction in SBP was 3.6, 6.7 and 6.1mmHg, and QALYs accrued were 0.427, 0.422 and 0.423 for TAU, S-MON and S-MAN respectively. There were no statistically significant differences in incremental costs or outcomes detected. On average S-MAN was dominated or extended dominated. The incremental cost per mmHg BP reduction from S-MON vs TAU is £137. Conclusion: On average S-MAN is an inefficient intervention. S-MON may be cost-effective, depending on the willingness to pay for a mmHg reduction in blood pressure, although it yielded fewer QALYs over the within-trial time horizon. Decision modelling is required to explore the longer-term costs and outcomes.

Item Type: Article
Uncontrolled Keywords: cost-effectiveness,hypertension,prevention,reduction
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: LivePure Connector
Date Deposited: 24 Jan 2020 03:27
Last Modified: 30 May 2020 23:54
URI: https://ueaeprints.uea.ac.uk/id/eprint/73770
DOI: 10.1007/s41669-020-00196-w

Actions (login required)

View Item View Item